September 18, 2017 / 7:00 AM / 5 months ago

Gates Foundation invests $40 million in UK immunotherapy company

LONDON (Reuters) - The Bill & Melinda Gates Foundation is to invest up to $40 million (29.41 million pounds) in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases.

    Oxford-based Immunocore has so far concentrated on developing its T-cell receptor medicines to fight cancer, where it has collaborations with Roche (ROG.S), GlaxoSmithKline (GSK.L), AstraZeneca (AZN.L) and Eli Lilly (LLY.N).

    The tie-up with the Gates Foundation will extend the work into finding and developing new treatments for tuberculosis, HIV and other infectious diseases.

    Reporting by Ben Hirschler; Editing by Mark Potter

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below